osimertinib
astrazeneca
['lung', 'lcsm,(-blcsm)', 'osimertinib']
adjuvant osimertinib reduced the risk of death by 51% compared with placebo for patients with egfr-mutated, stage ib, ii, or iiia non small cell lung cancer. #asco23 #oncology #nursing #lcsm #lungcancer 
Capturing the voice of nursing professionals in the oncology news landscape.